348 related articles for article (PubMed ID: 23031588)
21. Chemotherapy of leishmaniasis. Part XII: design, synthesis and bioevaluation of novel triazole integrated phenyl heteroterpenoids as antileishmanial agents.
Suryawanshi SN; Tiwari A; Kumar S; Shivahare R; Mittal M; Kant P; Gupta S
Bioorg Med Chem Lett; 2013 May; 23(10):2925-8. PubMed ID: 23582274
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of trifluralin analogues as antileishmanial agents.
Esteves MA; Fragiadaki I; Lopes R; Scoulica E; Cruz ME
Bioorg Med Chem; 2010 Jan; 18(1):274-81. PubMed ID: 19926293
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani.
Nakayama H; Desrivot J; Bories C; Franck X; Figadère B; Hocquemiller R; Fournet A; Loiseau PM
Biomed Pharmacother; 2007; 61(2-3):186-8. PubMed ID: 17360145
[TBL] [Abstract][Full Text] [Related]
24. Syntheses of new substituted triazino tetrahydroisoquinolines and beta-carbolines as novel antileishmanial agents.
Kumar A; Katiyar SB; Gupta S; Chauhan PM
Eur J Med Chem; 2006 Jan; 41(1):106-13. PubMed ID: 16356594
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of novel substituted quinazoline derivatives as antileishmanial agents.
Agarwal KC; Sharma V; Shakya N; Gupta S
Bioorg Med Chem Lett; 2009 Sep; 19(18):5474-7. PubMed ID: 19692240
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and Antileishmanial Activity of 1,2,4,5-Tetraoxanes against
Cabral LIL; Pomel S; Cojean S; Amado PSM; Loiseau PM; Cristiano MLS
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979089
[TBL] [Abstract][Full Text] [Related]
27. Design, synthesis and biological evaluation of 2-substituted quinolines as potential antileishmanial agents.
Gopinath VS; Pinjari J; Dere RT; Verma A; Vishwakarma P; Shivahare R; Moger M; Kumar Goud PS; Ramanathan V; Bose P; Rao MV; Gupta S; Puri SK; Launay D; Martin D
Eur J Med Chem; 2013 Nov; 69():527-36. PubMed ID: 24095747
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, structure-activity relationships, and biological studies of chromenochalcones as potential antileishmanial agents.
Shivahare R; Korthikunta V; Chandasana H; Suthar MK; Agnihotri P; Vishwakarma P; Chaitanya TK; Kancharla P; Khaliq T; Gupta S; Bhatta RS; Pratap JV; Saxena JK; Gupta S; Tadigoppula N
J Med Chem; 2014 Apr; 57(8):3342-57. PubMed ID: 24635539
[TBL] [Abstract][Full Text] [Related]
29. Arylanthranilodinitriles: a new biaryl class of antileishmanial agents.
Singh FV; Vatsyayan R; Roy U; Goel A
Bioorg Med Chem Lett; 2006 May; 16(10):2734-7. PubMed ID: 16503140
[TBL] [Abstract][Full Text] [Related]
30. Triazino indole-quinoline hybrid: a novel approach to antileishmanial agents.
Sharma R; Pandey AK; Shivahare R; Srivastava K; Gupta S; Chauhan PM
Bioorg Med Chem Lett; 2014 Jan; 24(1):298-301. PubMed ID: 24314395
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and molecular docking studies of 1-phenyl-4-glycosyl-dihydropyridines as potent antileishmanial agents.
Pandey VP; Bisht SS; Mishra M; Kumar A; Siddiqi MI; Verma A; Mittal M; Sane SA; Gupta S; Tripathi RP
Eur J Med Chem; 2010 Jun; 45(6):2381-8. PubMed ID: 20199824
[TBL] [Abstract][Full Text] [Related]
32. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.
Seifert K; Pérez-Victoria FJ; Stettler M; Sánchez-Cañete MP; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2007 Sep; 30(3):229-35. PubMed ID: 17628445
[TBL] [Abstract][Full Text] [Related]
34. Synthesis of 2-(pyrimidin-2-yl)-1-phenyl-2,3,4,9-tetrahydro-1H-beta-carbolines as antileishmanial agents.
Kumar R; Khan S; Verma A; Srivastava S; Viswakarma P; Gupta S; Meena S; Singh N; Sarkar J; Chauhan PM
Eur J Med Chem; 2010 Aug; 45(8):3274-80. PubMed ID: 20457476
[TBL] [Abstract][Full Text] [Related]
35. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species.
Nieto-Meneses R; Castillo R; Hernández-Campos A; Maldonado-Rangel A; Matius-Ruiz JB; Trejo-Soto PJ; Nogueda-Torres B; Dea-Ayuela MA; Bolás-Fernández F; Méndez-Cuesta C; Yépez-Mulia L
Exp Parasitol; 2018 Jan; 184():82-89. PubMed ID: 29191699
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antikinetoplastid activities of 3-substituted quinolinones derivatives.
Audisio D; Messaoudi S; Cojean S; Peyrat JF; Brion JD; Bories C; Huteau F; Loiseau PM; Alami M
Eur J Med Chem; 2012 Jun; 52():44-50. PubMed ID: 22472166
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and in vitro antileishmanial activity of 5-substituted-2'-deoxyuridine derivatives.
Peyron C; Benhida R; Bories C; Loiseau PM
Bioorg Chem; 2005 Dec; 33(6):439-47. PubMed ID: 16168460
[TBL] [Abstract][Full Text] [Related]
38. Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines.
Manda S; Khan SI; Jain SK; Mohammed S; Tekwani BL; Khan IA; Vishwakarma RA; Bharate SB
Bioorg Med Chem Lett; 2014 Aug; 24(15):3247-50. PubMed ID: 24980054
[TBL] [Abstract][Full Text] [Related]
39. Nanotized Curcumin and Miltefosine, a Potential Combination for Treatment of Experimental Visceral Leishmaniasis.
Tiwari B; Pahuja R; Kumar P; Rath SK; Gupta KC; Goyal N
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031196
[TBL] [Abstract][Full Text] [Related]
40. Targeting the human parasite Leishmania donovani: discovery of a new promising anti-infectious pharmacophore in 3-nitroimidazo[1,2-a]pyridine series.
Castera-Ducros C; Paloque L; Verhaeghe P; Casanova M; Cantelli C; Hutter S; Tanguy F; Laget M; Remusat V; Cohen A; Crozet MD; Rathelot P; Azas N; Vanelle P
Bioorg Med Chem; 2013 Nov; 21(22):7155-64. PubMed ID: 24080103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
